Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma

Authors

Robert Chen, City of Hope
Suzanne Allibone, The Lymphoma Service of the Christie NHS Foundation
Nancy L. Bartlett, Washington University School of Medicine in St. Louis
Pauline Brice, Hôpital Saint-Louis
Andy Chen, Oregon Health and Science University
Katrina Pose, Lymphoma and Cancer Survivorship Stanford Comprehensive Cancer Center
Lynn Rich, University of Rochester Medical Center
Vijay Bonthapally, Millennium Pharmaceuticals Inc.
Phillip M. Garfin, Seattle Genetics, Inc.
Michelle Fanale, The University of Texas MD Anderson Cancer Center

Journal

OncoTargets and Therapy

Publication Date

2016

Volume

2016

Issue

9

Inclusive Pages

2027-2034

Document Type

Open Access Publication

DOI

10.2147/OTT.S96175

Rights and Permissions

Robert Chen, Suzanne Allibone, Nancy L Bartlett, Pauline Brice, Andy Chen, Katrina Pose, Lynn Rich, Vijay Bonthapally, Phillip M Garfin, Michelle Fanale. Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma. OncoTargets and Therapy. April 2016. Volume 2016:9 Pages 2027—2034. DOI https://dx.doi.org/10.2147/OTT.S96175.

Recommended Citation

Chen, Robert; Allibone, Suzanne; Bartlett, Nancy L.; Brice, Pauline; Chen, Andy; Pose, Katrina; Rich, Lynn; Bonthapally, Vijay; Garfin, Phillip M.; and Fanale, Michelle, "Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma." OncoTargets and Therapy. 2016, 9. 2027-2034. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/5271